IRVINE, Calif., April 11, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced the publication of its 2023 Ethos and Sustainability Report. The report highlights Inari’s commitment to its ethos and important corresponding environmental, social and governance (ESG) initiatives. The report can be found on Inari’s website here.
“We are proud to issue our third annual Ethos and Sustainability Report and highlight the ESG-focused initiatives we implemented during the past year,” said Drew Hykes, CEO of Inari Medical. “2023 was a great year for Inari, our patients, and our employees, as we focused on activities that embodied the Inari ethos. Our 2023 Ethos and Sustainability Report summarizes these activities and reflects the responsibility that we feel towards all stakeholders.”
About Inari Medical, Inc.
Patients first. No small plans. Take care of each other. These are the guiding principles that form the ethos of Inari Medical. We are committed to improving lives in extraordinary ways by creating innovative solutions for both unmet and underserved health needs. In addition to our purpose-built solutions, we leverage our capabilities in education, clinical research, and program development to improve patient outcomes. We are passionate about our mission to establish our treatments as the standard of care for venous disease, including venous thromboembolism, chronic venous disease and beyond. We are just getting started. Learn more at www.inarimedical.com and connect with us on LinkedIn, X (Twitter), and Instagram.
Investor Contact:
John Hsu, CFA
VP, Investor Relations
949-658-3889
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$45.52 |
Daily Change: | 3.84 9.21 |
Daily Volume: | 1,636,919 |
Market Cap: | US$2.650B |
August 29, 2024 August 21, 2024 April 30, 2024 |
Surmodics is the global leader in surface modification technologies for intravascular medical devices and a leading provider of chemical components for in vitro diagnostic immunoassay tests and microarrays. Surmodics is pursuing highly differentiated whole-product solutions that are designed to address...
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB